Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 18,750 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00. Following the transaction, the chief executive officer now owns 379,534 shares in the company, valued at $29,580,879.96. This trade represents a 4.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

William Lewis also recently made the following trade(s):

• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $81.44 on Thursday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $81.96. The firm has a market capitalization of $14.57 billion, a price-to-earnings ratio of -14.67 and a beta of 1.11. The firm has a 50 day moving average of $72.69 and a 200 day moving average of $73.04.

Analysts Set New Price Targets

INSM has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Bank of America boosted their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Finally, Truist Financial reissued a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Institutional Investors Weigh In On Insmed

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jennison Associates LLC raised its stake in Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after acquiring an additional 4,560 shares during the period. Capital CS Group LLC bought a new stake in shares of Insmed during the 4th quarter valued at $586,000. Orion Portfolio Solutions LLC lifted its stake in shares of Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after buying an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC boosted its holdings in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after buying an additional 21,833 shares during the period. Finally, Vestal Point Capital LP increased its stake in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after buying an additional 850,000 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.